FocusCancer

Dynamics of drug response informs rational combination regimens

See allHide authors and affiliations

Science Signaling  20 Aug 2019:
Vol. 12, Issue 595, eaax9742
DOI: 10.1126/scisignal.aax9742

You are currently viewing the abstract.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution

Abstract

Metabolic plasticity in cancer has been linked to the development of drug-tolerant populations. In this issue of Science Signaling, Goldman et al. integrate metabolic plasticity with phenotypic state transitions to examine how this reprogramming can be therapeutically exploited.

View Full Text